MetLife Investment Management LLC Increases Stock Holdings in Hims & Hers Health, Inc. $HIMS

Key Points

• MetLife Investment Management LLC significantly increased its stake in Hims & Hers Health, buying 100,957 shares, bringing its total ownership to 215,753 shares valued at approximately $6.4 million.
• Recent insider trades saw CEO Andrew Dudum sell 660,000 shares valued at over $33 million, indicating a 22.96% decrease in his ownership of the company.
• Hims & Hers Health reported quarterly earnings with an EPS of $0.17, missing estimates by a small margin, and had a revenue increase of 72.6% year-over-year despite a slight miss on revenue expectations.

MetLife Investment Management LLC boosted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 87.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 215,753 shares of the company's stock after acquiring an additional 100,957 shares during the quarter. MetLife Investment Management LLC owned about 0.10% of Hims & Hers Health worth $6,376,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of HIMS. Mariner LLC raised its position in Hims & Hers Health by 77.4% in the fourth quarter. Mariner LLC now owns 19,943 shares of the company's stock worth $482,000 after acquiring an additional 8,699 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Hims & Hers Health by 71.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 18,002 shares of the company's stock worth $435,000 after acquiring an additional 7,476 shares in the last quarter. Stifel Financial Corp purchased a new position in Hims & Hers Health in the fourth quarter worth $257,000. Price T Rowe Associates Inc. MD raised its position in Hims & Hers Health by 291.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 420,348 shares of the company's stock worth $10,165,000 after acquiring an additional 312,908 shares in the last quarter. Finally, Beacon Pointe Advisors LLC raised its position in Hims & Hers Health by 71.2% in the fourth quarter. Beacon Pointe Advisors LLC now owns 52,172 shares of the company's stock worth $1,262,000 after acquiring an additional 21,690 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on HIMS shares. Piper Sandler reissued a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Price Performance

Shares of HIMS traded down $1.76 during trading hours on Friday, reaching $42.36. 16,080,388 shares of the company traded hands, compared to its average volume of 29,952,310. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock has a market capitalization of $9.57 billion, a PE ratio of 52.95, a price-to-earnings-growth ratio of 2.98 and a beta of 2.08. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a fifty day simple moving average of $49.98 and a 200 day simple moving average of $45.82.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same quarter last year, the company posted $0.06 earnings per share. The business's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer owned 63,222 shares in the company, valued at approximately $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.